Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/351396
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampDamasceno, Alfredo-
dc.typeArtigopt_BR
dc.titleWe know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?pt_BR
dc.contributor.authorFragoso, Y.D.a,bEmail Author, Arruda, N.M.c, Arruda, W.O.d, Brooks, J.B.B.a, Correa, E.C.e, Damasceno, A.f, Damasceno, C.A.g, Ferreira, M.L.B.c, Giacomo, M.C.B.h, Gomes, S.i, Gonçalves, M.V.M.j, Grzesiuk, A.K.k, Kaimen-Maciel, D.R.l, Lopes, J.l, Machado, S.C.N.m, Oliveira, C.L.S.a, Stella, C.R.A.V.-
dc.subjectEsclerose múltiplapt_BR
dc.subject.otherlanguageMultiple sclerosispt_BR
dc.description.abstractNatalizumab is a potent immunosuppressive monoclonal antibody used for the treatment of multiple sclerosis (MS). While definite guidelines for the safety of natalizumab prescriptions are available in all countries, there are no specific recommendations on how to withdraw the drug if the need arises. There are reports describing MS complications after natalizumab infusions were stopped. Most neurologists seem to stop natalizumab treatment according to their idea on how to best carry out the withdrawal. The present study shows the very different manners in which expert neurologists from 14 MS units in Brazil stopped natalizumab in their patients. The authors concluded that pharmacovigilance on natalizumab must persist after the drug is withdrawn in order to have enough data for adequate recommendationspt_BR
dc.relation.ispartofExpert review of neurotherapeuticspt_BR
dc.relation.ispartofabbreviationExpert rev. neurother.pt_BR
dc.publisher.cityAbingdonpt_BR
dc.publisher.countryReino Unidopt_BR
dc.publisherTaylor & Francispt_BR
dc.date.issued2014-
dc.date.monthofcirculationFeb.pt_BR
dc.language.isoengpt_BR
dc.description.volume14pt_BR
dc.description.issuenumber2pt_BR
dc.description.firstpage127pt_BR
dc.description.lastpage130pt_BR
dc.rightsFechadopt_BR
dc.sourceSCOPUSpt_BR
dc.identifier.issn1473-7175pt_BR
dc.identifier.eissn1744-8360pt_BR
dc.identifier.doi10.1586/14737175.2014.874947pt_BR
dc.identifier.urlhttps://www.tandfonline.com/doi/abs/10.1586/14737175.2014.874947pt_BR
dc.date.available2020-10-22T10:37:58Z-
dc.date.accessioned2020-10-22T10:37:58Z-
dc.description.provenanceSubmitted by Sanches Olivia (olivias@unicamp.br) on 2020-10-22T10:37:58Z No. of bitstreams: 0. Added 1 bitstream(s) on 2021-06-30T17:36:57Z : No. of bitstreams: 1 2-s2.0-84893060675.pdf: 261267 bytes, checksum: b015ba8b3164ea94dacb2c1e9fc328b0 (MD5)en
dc.description.provenanceMade available in DSpace on 2020-10-22T10:37:58Z (GMT). No. of bitstreams: 0 Previous issue date: 2014en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/351396-
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordFingolimodpt_BR
dc.subject.keywordJC viruspt_BR
dc.subject.keywordNatalizumabpt_BR
dc.subject.keywordRelapsespt_BR
dc.identifier.source2-s2.0-84893060675pt_BR
dc.creator.orcid0000-0002-7919-3989pt_BR
dc.type.formArtigopt_BR
dc.description.otherSponsorshipsem informaçãopt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-84893060675.pdf255.14 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.